دورية أكاديمية
At least one cyclic teriparatide administration can be helpful to delay initial onset of a new osteoporotic vertebral compression fracture
| العنوان: | At least one cyclic teriparatide administration can be helpful to delay initial onset of a new osteoporotic vertebral compression fracture |
|---|---|
| المساهمون: | Kyung Soo Suk, Hwan Mo Lee, Seong Hwan Moon, Hee June Kim, Hak Sun Kim, Jin Oh Park, Byung Ho Lee, Kim, Hak Sun, Moon, Seong Hwan, Park, Jin Oh, Suk, Kyung Soo, Lee, Hwan Mo |
| المصدر: | T201404481.pdf |
| سنة النشر: | 2014 |
| مصطلحات موضوعية: | Aged, 80 and over, Bone Density/drug effects, Bone Density Conservation Agents/administration & dosage, Bone Density Conservation Agents/pharmacology, Cohort Studies, Drug Administration Schedule, Female, Fractures, Compression/drug therapy, Compression/etiology, Humans, Incidence, Male, Middle Aged, Osteoporosis/complications, Osteoporotic Fractures/drug therapy, Osteoporotic Fractures/etiology, Retrospective Studies, Spinal Fractures/drug therapy, Spinal Fractures/etiology, Teriparatide/administration & dosage, Teriparatide/pharmacology, Time Factors, Treatment Outcome, Osteoporosis, duration, teriparatide, vertebral compression fracture |
| الوصف: | PURPOSE: Teriparatide markedly increases bone formation and strength, while reducing the incidence of new-onset osteoporotic vertebral compression fractures (OVCFs). In some countries, expenses for teriparatide use are covered by medical insurance for up to 6 months; however, the national medical insurance of the authors' country does not cover these expenses. This retrospective cohort study compared the therapeutic effects of teriparatide on the initial onset of a new OVCF after treatment of osteoporosis and/or related OVCFs with regard to therapeutic durations of longer than 3 months (LT3M) or shorter than 3 months (ST3M). MATERIALS AND METHODS: From May 2007 to February 2012, 404 patients who were prescribed and administered teriparatide and who could be followed-up for longer than 12 months were enrolled. They were divided into two groups depending on teriparatide duration: LT3M (n=132) and ST3M (n=272). RESULTS: The group with the teriparatide duration of LT3M showed significantly less development of an initial OVCF within 1 year (p=0.004, chi-square). Duration of teriparatide use, body mass index, pre-teriparatide lowest spinal bone mineral density, and severity of osteoporosis significantly affected multiple regression analysis results (p<0.05). Survival analysis of first new-onset OVCFs demonstrated a significantly better survival rate for the LT3M group (log rank, p=0.005). Also, the ST3M group showed a higher odds ratio of 54.00 for development of an initial OVCF during follow-up than the LT3M group (Mantel-Haenzel common odds ratio, p=0.006). CONCLUSION: At least one cyclic teriparatide administration is recommended to provide a protective effect against the initial onset of a new OVCF for up to one year after therapy. ; open |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | 1576~1583 |
| اللغة: | unknown |
| تدمد: | 0513-5796 1976-2437 |
| العلاقة: | YONSEI MEDICAL JOURNAL; J02813; OAK-2014-02641; https://ir.ymlib.yonsei.ac.kr/handle/22282913/138374Test; T201404481; YONSEI MEDICAL JOURNAL, Vol.55(6) : 1576-1583, 2014 |
| DOI: | 10.3349/ymj.2014.55.6.1576 |
| الإتاحة: | https://doi.org/10.3349/ymj.2014.55.6.1576Test https://ir.ymlib.yonsei.ac.kr/handle/22282913/138374Test |
| حقوق: | CC BY-NC-ND 2.0 KR ; https://creativecommons.org/licenses/by-nc-nd/2.0/krTest/ |
| رقم الانضمام: | edsbas.30EB9390 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 05135796 19762437 |
|---|---|
| DOI: | 10.3349/ymj.2014.55.6.1576 |